New York Genome Center, Inc.

New York Genome Center, Inc. (doing business as Nygc), a tax-exempt non-profit academic research institution headquartered in New York, New York, provides large-scale genomic sequencing, multi-omics analysis, and computational biology services to the National Institutes of Health and affiliated federal research agencies as both a prime contractor and as a grant recipient and sub-recipient.

Nygc operates across three primary capability domains: centralized omics resource services supporting precision medicine research initiatives; genome characterization and whole-exome sequencing platforms for large-scale genomic research; and single-cell and spatial multi-omics technology development and application including next-generation sequencing, RNA-sequencing, CRISPR screening, and advanced computational analysis of genomic and transcriptomic datasets. The vendor's customer concentration reflects dominance in life-sciences research funding. The National Heart Lung and Blood Institute alone accounts for nine awards carrying $1.04 billion in combined potential value (71% of the vendor's total portfolio ceiling). The National Cancer Institute follows with 27 awards valued at $199.5 million, and the National Institute of Mental Health holds nine awards at $149 million. These three funders represent the vast majority of the portfolio's potential value, though the National Human Genome Research Institute and the Office of the Director each carry 16–17 awards. The Department of Veterans Affairs Veterans Integrated Service Network 2 places 13 orders but in lower dollar increments ($1.1 million combined). This concentration—dominated by NIH institutes and precision-medicine research programs—reflects Nygc's positioning as a specialized genomics service provider rather than a vendor with broad federal reach.

Nygc holds four significant parent indefinite-delivery contracts. The Trans-Omics for Precision Medicine (TOPMed) Centralized Omics Resource single-award IDIQ, awarded by the National Heart Lung and Blood Institute on September 14, 2023, carries a $500 million ceiling and runs through September 2033; four delivery orders totaling approximately $17.3 million have been issued to date for centralized omics resource core services, RNA-sequencing, and data integration supporting the NHLBI's precision medicine portfolio. The National Cancer Institute awarded an NCI Genomic Characterization Centers multi-award IDIQ to Nygc on January 13, 2025, with a $149.2 million ceiling through January 2030, for large-scale whole-exome sequencing and high-resolution genomic characterization platforms. The BRAIN Initiative Cell Atlas Network (BICAN) Sequencing Core multi-award vehicle, issued by the National Institute on Drug Abuse on January 31, 2023, carries a $149 million ceiling through January 2030 and has funded two task orders to Nygc totaling over $69.9 million for brain cell sequencing and manual-of-operations development. A fourth single-award IDIQ from Veterans Integrated Service Network 2 (December 1, 2022, $356,920 ceiling, May 2027 completion) has generated four next-generation sequencing delivery orders for ongoing VA research studies. Recent representative task-order work includes a $5.86 million firm fixed-price delivery order from the National Heart Lung and Blood Institute (September 28, 2026) for centralized omics resource core services under TOPMed, a $69.86 million cost-no-fee order from the National Institute on Drug Abuse (May 29, 2023) for BICAN sequencing services across fiscal 2024 invoicing $3.8 million, and multiple $3.7 million to $7 million RNA-sequencing and omics-analysis orders from NHLBI spanning 2023–2025.

Activity has grown substantially year over year, from 10 awards in 2022 to 27 in 2024, before moderating to 15 in 2025 and 16 in 2026. Twelve awards with combined potential value of $81.3 million face ultimate completion within the next twenty-four months and will trigger recompete cycle activity. SCI-reported invoicing of federal service contracts shows concentration in FY2024, when Nygc reported $9.8 million across 130 FTEs, representing the largest invoiced volume in the source data; FY2022 captured $192 thousand across 4.6 FTEs. The source does not provide FY2023 or FY2025 SCI-reportable invoicing, indicating either zero-threshold invoicing below the $150,000 reporting floor or timing misalignment. On federal services contracts captured in SCI, government-paid rates ran median around $25.62 per hour, with senior labor pricing through $530.26 per hour and entry-level work at $10.73 per hour, reflecting a staffing profile spanning technicians, bioinformaticians, and senior research scientists. Across SCI-reportable prime contracts, Nygc self-performed all reported hours with zero subcontractor engagement share.

The vendor's federal grant footprint is substantial and distinct from contract work. Nygc holds or participates in prime and sub-recipient roles on NIH grants spanning the National Human Genome Research Institute (CFDA 93.172 for spatial multi-omics technology development, $2.677 million awarded June 2026), the National Cancer Institute (CFDA 93.396 for Paired-Break-Seq single-cell profiling, $270 thousand awarded May 2026; cancer biology CRISPR and CAR-T research), the National Institute of Mental Health (cooperative agreements for psychiatric genomics), the National Institute of General Medical Sciences (single-cell multiomics development), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (CFDA 93.865 for dGTEx statistical methods, $784 thousand, September 2024), the National Institute on Drug Abuse (BRAIN Initiative Cell Atlas Network sequencing core), the National Science Foundation (CFDA 47.084 for open-source DNA sequencer repurposing, $319 thousand, July 2025), and the Office of the Director (Somatic Mosaicism Across Human Tissues cooperative agreement, May 2023). As a sub-recipient, Nygc contributes sequencing operations, computational biology, multiomics data generation, and bioinformatics support to research programs at Weill Cornell Medicine, Columbia University, Cold Spring Harbor Laboratory, The Broad Institute, Jackson Laboratory, and others. Representative sub-recipient work includes computational biology support for genome-wide mutational integration under a Weill Cornell prime (August 2026), single-nucleus and spatial multiomic data generation for cancer research under a Columbia University prime (multiple sub-awards spanning 2022–2026), CRISPR screening and ECCITE-seq under Weill Cornell leadership (May 2026), and Paired-Tag histone-modification profiling under University of Pittsburgh (March 2026).

The vendor's prime-vs-sub split shows 75 prime awards (57% of the portfolio) and 56 sub-awards (43%), indicating balanced engagement as both an independent principal and a specialized subcontractor to larger research institutions. Nygc's teaming pattern reflects the structure of academic biomedical research: the vendor rarely places subcontractors on its own contracts but instead serves as a high-value sub-recipient on grants and cooperative agreements with academic medical centers and research institutions that lead multi-institutional initiatives. No set-aside designations appear across the source data; all awards are full-and-open procurements reflecting the specialized, non-competitive nature of genomics research infrastructure services.